Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
HBV
Type
Interventional
Phase
Phase 4
Design
Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Approximately 100 adults, cirrhotic or non-cirrhotic (capped at 50), CHB patients with hepatic decompensation, will receive initial treatment (Arm A) with or switch (Arm B) to TAF 25 mg/day for 144 weeks. For Initiation Arm, CHB patients with hepatic decompensation, who are currently not under HBV antiviral treatment will be enrolled. For Switch Arm, CHB patients who are currently with hepatic decompensation and virally suppressed under HBV NUC treatment (HBV DNA < 20 IU/mL) will be enrolled.Masking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 20 years and 100 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT04683341
Collaborators
Not Provided
Investigators
Principal Investigator: Ming-Lung Yu, Professor Hepatobiliary Division, Kaohsiung Medical University Hospital